SCHEMBL142886

SCHEMBL142886

O=[C]CCCCc1cccs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.53
TSHR P16473 2/20 0.47
NPC1 O15118 2/20 0.44
POLB P06746 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ADRA2A P08913 2/20 0.41
ADRA2B P18089 2/20 0.41
ADRA2C P18825 2/20 0.41
HCAR2 Q8TDS4 1/20 0.40
RAB9A P51151 1/20 0.40
CYP2C19 P33261 1/20 0.39
USP2 O75604 1/20 0.39
CASP3 P42574 1/20 0.38
CASP7 P55210 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
ASAH1 Q13510 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11577289 0.98 TAAR1 (0.52) TAAR1TSHRNPC1POLBSMN1; SMN2
SCHEMBL141983 0.98 TAAR1 (0.52) TAAR1TSHRNPC1POLBSMN1; SMN2
SCHEMBL144587 0.94 TAAR1 (0.55) TAAR1TSHRNPC1POLBSMN1; SMN2
SCHEMBL144121 0.86
SCHEMBL20146704 0.83 TAAR1 (0.73) TAAR1TSHRNPC1POLBSMN1; SMN2
SCHEMBL6734915 0.81 TAAR1 (0.70) TAAR1TSHRNPC1POLBSMN1; SMN2
SCHEMBL7116263 0.81 TAAR1 (0.70) TAAR1TSHRNPC1POLBSMN1; SMN2
SCHEMBL8571535 0.81 TAAR1 (0.70) TAAR1TSHRNPC1POLBSMN1; SMN2
SCHEMBL10722348 0.81 TAAR1 (0.53) TAAR1TSHRNPC1POLBSMN1; SMN2
SCHEMBL31538874 0.81 TAAR1 (0.53) TAAR1TSHRNPC1ADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240084308-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2024-03-14 US disclosed
US-20240034845-A1 POLYMER PARTICLES QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) 2024-02-01 US disclosed
EP-3384549-B1 SODIUM-ION ELECTROLYTE COMPOSITION UNIV DEAKIN (AU) 2024-01-17 EP disclosed
US-11834663-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2023-12-05 US disclosed
US-20230348674-A1 HYDROGELS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2023-11-02 US disclosed
WO-2023190111-A1 RAFT POLYMERIZATION REACTION SOLUTION AND RAFT POLYMERIZATION REACTION SOLUTION PRODUCTION METHOD テクノUMG株式会社 2023-10-05 WO disclosed
CN-113939544-B non-core-shell polymer particles 悉尼大学 2023-08-22 CN disclosed
CN-116615468-A Polymer particles 昆士兰科技大学 2023-08-18 CN disclosed
WO-2023121483-A1 IMMUNOSTIMULATORY COMPOSITIONS VICTORIA LINK LIMITED (NZ) 2023-06-29 WO disclosed
WO-2023102600-A1 SYNTHESIS OF AMPHIPHILIC BLOCK COPOLYMERS AND POLYMERIC NANOFIBERS PRODUCED THEREFROM NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2023-06-15 WO disclosed
WO-1992002513-A1 HETEROCYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-02-20 WO disclosed
US-4981847-A Tricyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-01-01 US disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed
EP-0360079-A1 Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-03-28 EP disclosed
EP-0336230-A2 Cyclic peptide antagonists of Substance P and Substance K FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-10-11 EP disclosed
US-4497738-A Analogous compounds of cephalosporins, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-02-05 US disclosed
EP-0017138-B1 ANALOGOUS COMPOUNDS OF CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-07-04 EP disclosed
EP-0070575-A2 New starting compounds for preparing analogous compounds of cephalosporins and processes for their preparation FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-01-26 EP disclosed
US-4339449-A Analogous compounds of cephalosporins, and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) 1982-07-13 US disclosed
EP-0017138-A2 Analogous compounds of cephalosporins, processes for their preparation, and pharmaceutical composition containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834663-B2 Fibrotic treatment MMP1, ENPEP, RNPEP TAAR1 3576/4885TSHR 2551/4885NPC1 3429/4885
US-20230348674-A1 HYDROGELS PHYKPL, TST, PHOSPHO1 TAAR1 2105/4885TSHR 1684/4885NPC1 4885/4885
US-20240084308-A1 FIBROTIC TREATMENT MMP1, ENPEP, RNPEP TAAR1 3576/4885TSHR 2551/4885NPC1 3429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.